Prior Authorization Information

The Gilead Advancing Access® program can provide information to your office to help you understand your patients’ insurance coverage for their Gilead medication including determining Prior Authorizations and appeals requirements.

Get Your Patients Started With Advancing Access

Support By Phone
Call 1-800-226-20561-800-226-2056 from Monday – Friday, 9am to 8pm ET. Callers can also leave a confidential message any time and day of the week.

Enroll a Patient
Print and complete the Advancing Access Enrollment Form with your patient. Have them sign the form and fax it to 1-800-216-68571-800-216-6857.

Multilingual help is available. Notify our counselors if non-English assistance is needed. We will do our best to support specific requests.

Additional Prior Authorization Support: CoverMyMeds®

Prior Authorization (PA) requests can be submitted by using CoverMyMeds.

  • CoverMyMeds supports PA requests for
    • GENVOYA® (elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide)
    • ODEFSEY® (emtricitabine / rilpivirine / tenofovir alafenamide)
    • STRIBILD® (elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil fumarate)
    • COMPLERA® (emtricitabine / rilpivirine / tenofovir disoproxil fumarate)
  • Receive automatic notifications when a pharmacy starts a PA request for your patient
  • Take advantage of electronic PAs (ePAs) used by participating healthcare plans. Most ePA transactions are determined within 24 hours

Sign up at covermymeds.com by clicking "CREATE A FREE ACCOUNT." Or, for personal assistance, call 1-866-452-50171-866-452-5017. Support is available Monday through Friday from 8am to 11pm ET and on Saturday from 8am to 3pm ET.

COMPLERA, GENVOYA, ODEFSEY, STRIBILD are trademarks of Gilead Sciences, Inc. or its related companies.

By following this link, you are leaving this Gilead website. Gilead provides these links as a convenience. But these sites are not controlled by Gilead. Gilead is not responsible for their content or your use of them.

Leave Site Go Back